rs10277501 - LINC02889 - SNX13

Magnitude 2.8 · 1 study on file

Reported associations

• Polygenic Risk Scores and the Need for Pharmacotherapy in Neonatal Abstinence Syndrome - Unknown journal (n.d.) · Unknown authors · PubMed 35974158

  ABSTRACT: Objectives: To identify genetic variants associated with NAS through a Genome Wide Association Study (GWAS) and estimate a Polygenic Risk Score (PRS) model for NAS. Design: A prospective case-control study included 476 in-utero opioid-exposed term neonates. A GWAS of 1000 Genomes-imputed genotypes was performed to identify variants associated with need for pharmacotherapy for NAS. PRS models for estimating genetic predisposition were generated via a nested cross-validation approach using 382 neonates of European ancestry. PRS predictive ability, discrimination, and calibration were assessed. Results: Cross-ancestry GWAS identified one intergenic locus on chromosome 7 downstream of SNX13 exhibiting genome-wide association with need for pharmacotherapy. PRS models derived from the

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.